BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BMEYE Announces CE Mark Approval of Nexfin(TM)


7/23/2007 8:46:30 AM

AMSTERDAM, July 23 /PRNewswire/ -- BMEYE(TM) announced today CE Mark approval of Nexfin(TM), their newly developed line of accurate and easy to use hemodynamic monitors. The Nexfin(TM) monitors provide accurate and easy to use continuous non-invasive blood pressure and cardiac output monitoring.

"BMEYE(TM) was established to develop and market innovative technology that will transform the practice of medicine in hemodynamic patient monitoring. We are pleased and gratified by the CE Mark approval enabling us to market the Nexfin(TM) to cardiologists and any clinician who needs to measure continuous non-invasive blood pressure and cardiac output easily and accurately", said Bill Bednarski, CEO of BMEYE(TM). "The Nexfin(TM) is cost effective and will significantly improve patient care."

BMEYE(TM), based in Amsterdam and St. Louis, develops and markets innovative medical technology with broad applications in a variety of clinical settings. The focus of BMEYE(TM) is on accurate and easy to use non-invasive hemodynamic monitoring. The Nexfin(TM) family of monitors use an easy to apply finger sensor to produce accurate continuous non-invasive blood pressure and cardiac output data displayed on an intuitive touchscreen.

Patents pending. For more information please check our web site at www.bmeye.com.

BMEYE

CONTACT: Contact Information: Bill Bednarski, CEO BMEYE, Academic MedicalCenter, Suite K2-245, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands,Phone: +31-(0)20-566-7720, Email: bill.bednarski@bmeye.com; Center forEmerging Technologies, 4041 Forest Park Avenue, St. Louis, Missouri, 63108,USA, Phone: +1-(925)270-0741



Read at BioSpace.com

BMEYE
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES